Diagnostic utility of Ki-67 proliferation index, PSA, and other immunohistochemical markers in prostatic basal cell carcinoma: A review of 24 cases in the current literature and discussion on current treatment and diagnostics
Open Access
- 10 May 2026
- journal article
- review article
- Published by SAGE Publications in Rare Tumors
- Vol. 18
Abstract
Background: Basal cell carcinoma (BCC) of the prostate is a rare and poorly characterized malignancy distinct from conventional prostatic adenocarcinoma. Due to its rarity, diagnostic challenges arise, often leading to misclassification and delayed management. Immunohistochemical markers such as Ki-67 proliferation index and prostate-specific antigen (PSA) levels may aid in distinguishing BCC from typical adenocarcinoma, but data remain limited. Methods: This case series review study retrospectively analyzes published case reports and series spanning from 1988 to 2023 to evaluate Ki-67 staining patterns, PSA levels, and other immunohistochemical features to identify distinguishing characteristics of prostatic BCC. Data extracted included patient demographics, PSA levels at presentation, Ki-67 proliferation index values, and results of other immunohistochemical staining (i.e., PSA, P63). Results: Of the 24 BCC cases included in the final analysis, 20 reported PSA level at first presentation (mean: 2.56 ng/mL, range 0.08-7.3 ng/mL, normal range <4), 15 reported PSA IHC staining, and only 13 reported Ki-67 percentage values obtained through primary tumor biopsy staining (mean: 46.88%, range 0-80%). In comparison, Ki-67 expression numbers from National Comprehensive Cancer Network (NCCN) for prostate adenocarcinoma report varied Ki-67 expressions between risk groups: low-risk patients averaged 5.1% ± 3.8%, intermediate-risk patients averaged 7.4% ± 6.8%, and high-risk patients averaged 12.0% ± 12.4%. Various immunohistochemical staining was also collected yielding positive staining with Ki-67 in 13/13 cases, HMWCK/34βE12 in 14/14 cases, P63 in 14/14 cases, and BCL-2 in 12/13 cases. Conclusion: This retrospective analysis suggests that prostatic BCC may be characterized by higher Ki-67 proliferation indices and lower PSA levels compared to typical prostatic adenocarcinoma. This review further explores and proposes the potential of combining Ki-67 and PSA assessments along with other biomarkers to aid in distinguishing BCC from conventional prostate cancers, facilitating earlier recognition and appropriate management of this rare malignancy.Keywords
This publication has 28 references indexed in Scilit:
- Basal cell carcinoma of the prostate: unusual subtype of prostatic carcinomaInternational Journal of Clinical Oncology, 2010
- Basaloid carcinoma of the prostate: a case report and review of the literatureEuropean Journal of Cancer Care, 2008
- Basal cell carcinoma of the prostate: Report of a case and review of the published reportsInternational Journal of Urology, 2008
- Basal Cell Carcinoma of the Prostate: A Clinicopathologic Study of 29 CasesAmerican Journal of Surgical Pathology, 2007
- Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expressionJournal of Clinical Pathology, 2005
- Adenoid-basal cell tumor of the prostate gland: A case report: Histomorphologic and immunohistochemical featuresInternational Urology and Nephrology, 2003
- Adenoid cystic carcinoma of the prostate: A case report with immunohistochemical and in situ hybridization staining for prostate‐specific antigenInternational Journal of Urology, 2001
- Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67Human Pathology, 1998
- Adenoid cystic carcinoma of the prostate gland: pathological review with a case reportYonsei Medical Journal, 1991
- Adenoid Cystic-Like Tumor of the Prostate Gland: A Report of Two Cases and Review of the Literature on “Adenoid Cystic Carcinoma” of the ProstateAmerican Journal of Clinical Pathology, 1988